• 1
    Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet. 1975; 1: 883886.
  • 2
    Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron. 1977; 18: 182184.
  • 3
    Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol. 2002; 33: 121126.
  • 4
    Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 1998; 32: 992999.
  • 5
    Launay-Vacher V, Izzedine H, Rey JB, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004; 10: CR209CR212.
  • 6
    Dogan E, Izmirli M, Ceylan K, et al. Incidence of renal insufficiency in cancer patients. Adv Ther. 2005; 22: 357362.
  • 7
    Cockcroft DW, Gault MH. Prediction of CrCl from serum creatinine. Nephron. 1976; 16: 3141.
  • 8
    Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000; 11: 0828.
  • 9
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39( suppl 1): S1S266.
  • 10
    VidalSA, ed. Vidal Dictionary. Paris, France: Vidal Editions; 1999.
  • 11
    Thompson PDR. Physicians Desk Reference. 60th ed. Montvale, NJ: Thomson Healthcare; 2006.
  • 12
    Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia, Penn: American College of Physicians-American Society of Internal Medicine; 1999.
  • 13
    Launay-Vacher V, Karie S, Deray G, GPR Anticancer. Guide to Prescription Medications for Patients with Renal Insufficiency. 3rd ed [in French]. Paris, France: Meditions International; 2005.
  • 14
    U.S. National Library of Medicine. PubMed database. Available at URL: Accessed March 2006.
  • 15
    Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999; 13: 7990.
  • 16
    Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis. 2005; 46: 233241.
  • 17
    Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16: 763773.
  • 18
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 17481756.
  • 19
    Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995; 87: 573580.
  • 20
    Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int. 2005; 67: 706713.
  • 21
    Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005; 11: 555565.